Sex Steroid Hormones and Fracture in a Multiethnic Cohort of Women: The Women’s Health Initiative Study (WHI)
Open Access
- 25 January 2017
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (5) , 1538-1547
Abstract
Context: We hypothesize that endogenous sex steroids are associated with fracture risk independent of race/ethnicity. Design and Setting: We performed a nested case-control study within the prospective Women’s Health Initiative Observational Study. Incident nonspine fractures were identified in 381 black, 192 Hispanic, 112 Asian, and 46 Native American women over an average of 8.6 years. A random sample of 400 white women who experienced an incident fracture was chosen. One control was selected per case and matched on age, race/ethnicity, and blood draw date. Bioavailable estradiol (BioE2), bioavailable testosterone (BioT), and sex hormone–binding globulin (SHBG) were measured using baseline fasting serum. Conditional logistic regression models calculated the odds ratio (OR) and 95% confidence interval (CI) of fracture across tertiles of hormone. Results: In multivariable and race/ethnicity-adjusted models, higher BioE2 (>8.25 pg/mL) and higher BioT (>13.3 ng/dL) were associated with decreased risk of fracture (OR, 0.65; 95% CI, 0.50 to 0.85; P trend = 0.001 and OR, 0.76; 95% CI, 0.60 to 0.96; P trend = 0.02, respectively). The interaction term between race/ethnicity and either BioE2 or BioT was not significant. There was no association between SHBG and fracture risk. In models stratifying by race/ethnicity, higher BioE2 was associated with a lower risk of fracture in both white women (OR, 0.56; 95% CI, 0.36 to 0.87) and black women (OR, 0.61; 95% CI, 0.39 to 0.96). Higher BioT was associated with a significantly lower fracture risk in only black women (OR, 0.65; 95% CI, 0.43 to 1.00), P trend = 0.03. Conclusions: Serum BioE2 and BioT are associated with fracture risk in older women irrespective of race/ethnicity and independent of established risk factors for fracture.Keywords
This publication has 32 references indexed in Scilit:
- Low androstenedione/sex hormone binding globulin ratio increases fracture risk in postmenopausal women. The Women's Health in the Lund Area studyMaturitas, 2013
- Baseline serum estradiol and fracture reduction during treatment with hormone therapy: The Women's Health Initiative randomized trialOsteoporosis International, 2009
- Associations of Serum Sex Hormone-Binding Globulin and Sex Hormone Concentrations with Hip Fracture Risk in Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 2008
- A prospective study of sex steroids, sex hormone-binding globulin, and non-vertebral fractures in women and men: the Tromsø StudyEuropean Journal of Endocrinology, 2007
- Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trialsMenopause, 2004
- Walking Compared with Vigorous Exercise for the Prevention of Cardiovascular Events in WomenNew England Journal of Medicine, 2002
- Serum Estradiol and Sex Hormone-Binding Globulin and the Risk of Hip Fracture in Elderly Women: The EPIDOS StudyJournal of Bone and Mineral Research, 2000
- The rand 36‐item health survey 1.0Health Economics, 1993
- Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperatureThe Journal of Steroid Biochemistry and Molecular Biology, 1982
- Plasma androstenedione and oestrone levels in normal and osteoporotic postmenopausal women.BMJ, 1977